128 related articles for article (PubMed ID: 12910567)
1. Treatment of primary Sjögren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results.
Cummins MJ; Papas A; Kammer GM; Fox PC
Arthritis Rheum; 2003 Aug; 49(4):585-93. PubMed ID: 12910567
[TBL] [Abstract][Full Text] [Related]
2. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan; 95(1):38-44. PubMed ID: 12539025
[TBL] [Abstract][Full Text] [Related]
3. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjögren's syndrome.
Pillemer SR; Brennan MT; Sankar V; Leakan RA; Smith JA; Grisius M; Ligier S; Radfar L; Kok MR; Kingman A; Fox PC
Arthritis Rheum; 2004 Aug; 51(4):601-4. PubMed ID: 15334433
[TBL] [Abstract][Full Text] [Related]
4. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group.
Ship JA; Fox PC; Michalek JE; Cummins MJ; Richards AB
J Interferon Cytokine Res; 1999 Aug; 19(8):943-51. PubMed ID: 10476942
[TBL] [Abstract][Full Text] [Related]
5. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.
Petrone D; Condemi JJ; Fife R; Gluck O; Cohen S; Dalgin P
Arthritis Rheum; 2002 Mar; 46(3):748-54. PubMed ID: 11920411
[TBL] [Abstract][Full Text] [Related]
6. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X; Ravaud P; Steinfeld S; Baron G; Goetz J; Hachulla E; Combe B; Puéchal X; Pennec Y; Sauvezie B; Perdriger A; Hayem G; Janin A; Sibilia J
Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
[TBL] [Abstract][Full Text] [Related]
7. [Interferon alpha (IFNalpha) treatment for Sjögren's syndrome].
Shiozawa K; Shiozawa S
Nihon Rinsho; 2006 Jul; 64(7):1345-53. PubMed ID: 16838655
[TBL] [Abstract][Full Text] [Related]
8. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial.
Sankar V; Brennan MT; Kok MR; Leakan RA; Smith JA; Manny J; Baum BJ; Pillemer SR
Arthritis Rheum; 2004 Jul; 50(7):2240-5. PubMed ID: 15248223
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome.
Walters MT; Rubin CE; Keightley SJ; Ward CD; Cawley MI
Scand J Rheumatol Suppl; 1986; 61():253-8. PubMed ID: 3296153
[TBL] [Abstract][Full Text] [Related]
10. Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study.
Streckfus C; Bigler L; Navazesh M; Al-Hashimi I
Clin Oral Investig; 2001 Jun; 5(2):133-5. PubMed ID: 11480812
[TBL] [Abstract][Full Text] [Related]
11. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
Hu W; Qian X; Guo F; Zhang M; Lyu C; Tao J; Gao Z; Zhou Z
Chin Med J (Engl); 2014; 127(15):2721-6. PubMed ID: 25146603
[TBL] [Abstract][Full Text] [Related]
12. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome.
Shiozawa S; Tanaka Y; Shiozawa K
J Interferon Cytokine Res; 1998 Apr; 18(4):255-62. PubMed ID: 9568728
[TBL] [Abstract][Full Text] [Related]
13. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
Fox RI; Dixon R; Guarrasi V; Krubel S
Lupus; 1996 Jun; 5 Suppl 1():S31-6. PubMed ID: 8803908
[TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J; van Imhoff GW; Spijkervet FK; Roodenburg JL; Wolbink GJ; Mansour K; Vissink A; Kallenberg CG; Bootsma H
Arthritis Rheum; 2005 Sep; 52(9):2740-50. PubMed ID: 16142737
[TBL] [Abstract][Full Text] [Related]
15. A comparison of salivary gland hypofunction in primary and secondary Sjögren's syndrome.
Dawson LJ; Holt DJ; Higham SM; Longman LP; Field EA
Oral Dis; 2001 Jan; 7(1):28-30. PubMed ID: 11354918
[TBL] [Abstract][Full Text] [Related]
16. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Steinfeld SD; Tant L; Burmester GR; Teoh NK; Wegener WA; Goldenberg DM; Pradier O
Arthritis Res Ther; 2006; 8(4):R129. PubMed ID: 16859536
[TBL] [Abstract][Full Text] [Related]
17. A third study on the use of orally administered anhydrous crystalline maltose for relief of dry mouth in primary Sjögren's syndrome.
Fox PC; Cummins MJ; Cummins JM
J Altern Complement Med; 2002 Oct; 8(5):651-9. PubMed ID: 12470447
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study.
Ono M; Takamura E; Shinozaki K; Tsumura T; Hamano T; Yagi Y; Tsubota K
Am J Ophthalmol; 2004 Jul; 138(1):6-17. PubMed ID: 15234277
[TBL] [Abstract][Full Text] [Related]
19. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial.
Alves MB; Motta AC; Messina WC; Migliari DA
Quintessence Int; 2004 May; 35(5):392-6. PubMed ID: 15130080
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, density, and manifestations of oral Candida albicans in patients with Sjögren's syndrome.
Rhodus NL; Bloomquist C; Liljemark W; Bereuter J
J Otolaryngol; 1997 Oct; 26(5):300-5. PubMed ID: 9343767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
